Bank of Nova Scotia Sells 308,864 Shares of Humana Inc. $HUM

Bank of Nova Scotia decreased its holdings in shares of Humana Inc. (NYSE:HUM) by 85.6% in the first quarter, HoldingsChannel reports. The firm owned 51,929 shares of the insurance provider’s stock after selling 308,864 shares during the quarter. Bank of Nova Scotia’s holdings in Humana were worth $9,004,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in HUM. Revolve Wealth Partners LLC bought a new stake in shares of Humana in the 4th quarter worth $202,000. Woodline Partners LP boosted its stake in Humana by 460.0% during the first quarter. Woodline Partners LP now owns 10,192 shares of the insurance provider’s stock valued at $2,697,000 after buying an additional 8,372 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in shares of Humana by 53.7% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,293 shares of the insurance provider’s stock worth $316,000 after buying an additional 452 shares during the last quarter. Cresset Asset Management LLC increased its position in Humana by 10.3% during the second quarter. Cresset Asset Management LLC now owns 2,369 shares of the insurance provider’s stock valued at $581,000 after acquiring an additional 222 shares during the last quarter. Finally, WINTON GROUP Ltd boosted its holdings in Humana by 58.5% during the 2nd quarter. WINTON GROUP Ltd now owns 2,381 shares of the insurance provider’s stock valued at $582,000 after acquiring an additional 879 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Evercore upped their target price on Humana from $250.00 to $370.00 in a report on Thursday, June 11th. William Blair assumed coverage on shares of Humana in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. UBS Group restated a “neutral” rating on shares of Humana in a research report on Monday, June 15th. Wells Fargo & Company raised Humana from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $227.00 to $502.00 in a research note on Monday, July 13th. Finally, Seaport Research Partners lowered shares of Humana to a “neutral” rating in a research report on Wednesday, May 20th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $327.17.

Humana Stock Down 0.2%

HUM opened at $388.56 on Monday. The company has a market cap of $46.65 billion, a PE ratio of 41.56, a P/E/G ratio of 2.12 and a beta of 0.71. Humana Inc. has a 52 week low of $163.11 and a 52 week high of $428.88. The business has a 50 day moving average price of $364.10 and a two-hundred day moving average price of $264.93. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.66.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping analysts’ consensus estimates of $9.97 by $0.34. Humana had a return on equity of 10.45% and a net margin of 0.82%.The firm had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. During the same quarter in the prior year, the company posted $11.58 earnings per share. Humana’s quarterly revenue was up 23.5% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, research analysts anticipate that Humana Inc. will post 9.46 EPS for the current year.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.